Samuel Bjork

Partner

Samuel is a Partner at Digitalis.

He serves as a director on the boards of Bonum Therapeutics, Elemental Machines, EpiBiologics, T-Therapeutics, and Terray Therapeutics. He has also served as a board director of PetMedix (acquired by Zoetis) and board observer of Good Therapeutics (acquired by Roche), Scout Bio, Nuvig Therapeutics, and Switch Therapeutics.

Prior to Digitalis, Samuel was a member of the healthcare and clean energy practices at the Boston Consulting Group. He received graduate degrees from Cambridge and Oxford University as a Marshall Scholar and an A.B. in Chemistry from Harvard University.

LinkedIn


COMPANIES

Ascend

Bonum Therapeutics

Code Ocean
Elegen

Elemental Machines
EpiBiologics

Faeth Therapeutics
Galatea Bio

Good Therapeutics

Kingdom Supercultures

Nuvig Therapeutics

Onc.AI

PetMedix

Rejuvenate Bio

SeQure Dx

ScoutBio
Switch Therapeutics
T-Therapeutics
Terray Therapeutics